Paradigm Biopharmaceuticals Ltd

Healthcare AU PAR


Last update at 2024-02-22T04:59:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -51.91001M -39.24958M -34.29718M -12.29889M -15.62754M
Minority interest - - - - -
Net income -51.91001M -39.27822M -43.04688M -16.03090M -26.23154M
Selling general administrative 6.56M 7.93M 8.75M 4.17M 4.05M
Selling and marketing expenses - - - - -
Gross profit 0.03M -0.06453M -0.07859M - 2.98M
Reconciled depreciation - 0.06M 0.21M 0.08M 0.00835M
Ebit -60.03851M -39.22095M -34.25946M -12.26472M -5.02355M
Ebitda -51.89360M -39.15998M -34.04940M -12.05160M -5.01520M
Depreciation and amortization - 0.06M 0.21M 0.21M 0.00835M
Non operating income net other - - - - -
Operating income -51.89360M -39.22095M -34.25946M -12.26472M -5.02355M
Other operating expenses 60.09M 48.07M 43.41M 17.17M 11.95M
Interest expense 0.02M 0.03M 0.04M 0.03M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.41M 0.05M 0.04M 0.03M 0.26M
Net interest income 1.39M 0.02M 0.17M -0.03417M 0.26M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.03M 8.75M 3.73M 10.60M
Total revenue 0.05M 0.08M 0.02M 4.70M 3.25M
Total operating expenses 60.07M 47.93M 43.31M 17.17M 11.95M
Cost of revenue 0.02M 0.14M 0.10M - -
Total other income expense net 6.74M -0.02863M -0.03772M -0.03417M -10.60399M
Discontinued operations - - - - -
Net income from continuing ops -51.91001M -39.24958M -34.29718M -12.29889M -15.62754M
Net income applicable to common shares -51.91001M -39.24958M -34.29718M -12.29889M -15.62754M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 67.07M 50.69M 84.79M 112.36M 85.51M
Intangible assets 2.95M 2.95M 2.95M 2.95M 2.98M
Earning assets - - - - -
Other current assets - 0.78M 1.43M 0.94M 0.14M
Total liab 13.39M 8.38M 6.52M 4.18M 2.70M
Total stockholder equity 53.68M 42.31M 78.27M 108.18M 82.81M
Deferred long term liab - - - - -
Other current liab 0.78M 0.59M 0.67M 0.49M 0.43M
Common stock 209.83M 147.19M 146.99M 145.87M 109.47M
Capital stock 209.83M 147.19M 146.99M 145.87M 109.47M
Retained earnings -163.51401M -114.01554M -75.22823M -41.26855M -30.73482M
Other liab 0.11M 0.08M 0.11M 0.07M -
Good will - - - - -
Other assets - 0.00000M 0.10M 0.10M -
Cash 56.33M 39.67M 71.03M 103.92M 72.34M
Cash and equivalents - - - - -
Total current liabilities 13.04M 7.83M 5.79M 3.36M 2.70M
Current deferred revenue - - - - -
Net debt -55.99142M -39.05774M -70.28314M -103.04855M -72.33617M
Short term debt 0.10M 0.15M 0.13M 0.12M 6.50M
Short long term debt - - - - -
Short long term debt total 0.34M 0.62M 0.75M 0.87M -
Other stockholder equity -0.42878M 9.13M 6.51M 3.59M 4.07M
Property plant equipment 0.34M 0.57M 0.76M 0.94M 0.02M
Total current assets 63.79M 47.17M 80.98M 108.37M 82.51M
Long term investments - - 0.10M 0.10M -
Net tangible assets 50.73M 39.37M 75.33M 105.23M 79.82M
Short term investments 0.05M 0.05M 0.05M 0.75M 6.50M
Net receivables 6.81M 6.72M 8.51M 3.51M 3.53M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 12.16M 7.09M 4.99M 2.75M 2.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.36M 9.13M 6.51M 3.59M 4.07M
Additional paid in capital - - - - -
Common stock total equity - - - 145.87M 109.47M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 3.01M
Deferred long term asset charges - - - - -
Non current assets total 3.28M 3.52M 3.81M 3.99M 3.01M
Capital lease obligations 0.34M 0.62M 0.75M 0.87M -
Long term debt total 0.14M 0.37M 0.62M 0.75M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments - - 0.70M 5.75M -6.50000M
Change to liabilities 5.07M 2.10M 2.20M 0.75M 1.13M
Total cashflows from investing activities 0.00000M 0.00000M 0.67M 5.62M -6.52198M
Net borrowings -0.10449M -0.13517M -0.12185M 1.80M 1.80M
Total cash from financing activities 62.53M 0.07M 1.00M 36.05M 82.78M
Change to operating activities -0.10277M 0.54M -0.88882M -0.05527M -0.04514M
Net income -51.91001M -39.27822M -34.33491M -12.33305M -26.23154M
Change in cash 16.66M -31.36057M -32.88726M 31.59M 69.89M
Begin period cash flow 39.67M 71.03M 103.92M 72.34M 2.45M
End period cash flow 56.33M 39.67M 71.03M 103.92M 72.34M
Total cash from operating activities -45.18628M -39.21725M -34.92948M -10.09006M -6.36510M
Issuance of capital stock 65.99M - 1.02M 36.84M 88.05M
Depreciation 0.15M 0.06M 0.21M 0.21M 0.00835M
Other cashflows from investing activities 0.00000M 0.00000M 0.70M 5.75M -6.50000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.36M 1.79M -5.04870M 0.02M -0.79745M
Sale purchase of stock -3.76487M 0.00000M 1.02M -2.58845M -5.26972M
Other cashflows from financing activities 0.31M 0.07M -0.01817M 1.80M -6.52198M
Change to netincome 1.24M 2.41M 2.89M 1.28M 8.97M
Capital expenditures 0.00000M 0.00000M 0.03M 0.13M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.95M 0.05M 0.26M 1.12M 0.09M
Stock based compensation - - - - -
Other non cash items - 39.22M 34.09M 12.22M 15.62M
Free cash flow -45.18628M -39.21725M -34.96112M -0.13089M -0.02198M


  • Previous Close 0.34
  • Market Cap126.43M
  • Volume183242
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-59.88485M
  • Revenue TTM0.05M
  • Revenue Per Share TTM0.0
  • Gross Profit TTM 0.03M
  • Diluted EPS TTM-0.18


ASX : PAR announces annual results, emphasizing shareholder value with a final dividend declaration.
View all ASX announcements Click Here

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Paradigm Biopharmaceuticals Ltd
0.03 7.25% 0.37 0.0 0.0 2703.82 2.26 1393.74 -1.2559
0.75 0.26% 285.02 36.63 31.35 9.71 5.25 11.02 35.26
Telix Pharmaceuticals Ltd
-0.03 0.27% 10.97 0.0 60.98 9.99 46.85 9.79 -135.9258
Neuren Pharmaceuticals Ltd
0.05 0.25% 20.18 45.86 38.76 33.42 32.44 198.10 53.50
Imugene Ltd
0.0 0.0% 0.11 0.0 0.0 69.06 4.29 0.0 -12.9293

Reports Covered

Stock Research & News


Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Paradigm Biopharmaceuticals Ltd

500 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Founder, MD & Exec. Chairman 1959
Dr. Donna L. Skerrett M.D., MS Chief Medical Officer and Exec. Director 1957
Mr. Justin Cahill Chief Financial Officer NA
Dr. Ravi Krishnan Chief Scientific Officer NA
Mr. Simon White Director of Investor Relations NA
Dr. Michael Imperiale Global Head of Drug Safety & MPS NA
Ms. Beverley Huttmann Commercial Head NA
Ms. Michelle Coffey Global Head of Regulatory Affairs NA
Dr. Mukesh Ahuja Global Clinical Head of OA NA
Mr. Marco Polizzi Exec. Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).